-
Drosophila deoxyribonucleoside kinase mutants with enhanced ability to phosphorylate purine analogsKnecht, Wolfgang ...Transduced deoxyribonucleoside kinases (dNK) can be used to kill recipient cells in combination with nucleoside prodrugs. The Drosophila melanogaster multisubstrate dNK (Dm-dNK) displays a superior ... turnover rate and has a great plasticity regarding its substrates. We used directed evolution to create Dm-dNK mutants with increased specificity for several nucleoside analogs (NAs) used as anticancer or antiviral drugs. Four mutants were characterized for the ability to sensitize Escherichia coli toward analogs and for their substrate specificity and kinetic parameters. The mutants had a reduced ability to phosphorylate pyrimidines, while the ability to phosphorylate purine analogs was relatively similar to the wild-type enzyme. We selected twomutants, for expression in the osteosarcoma 143B, the glioblastoma U-87M-G and the breast cancer MCF7 cell lines. The sensitivities of the transduced cell lines in the presence of the NAs fludarabine (F-AraA), cladribine (CdA),vidarabine and cytarabine were compared to the parental cell lines. The sensitivity of 143B cells was increased by 470-fold in the presence of CdA andof U-87M-G cells by 435-fold in the presence of F-AraA. We also show that a choice of the selection and screening system plays a crucial role when optimizing suicide genes by directed evolution.Vir: Gene therapy. - ISSN 0969-7128 (Letn. 14, št. 17, 2007, str. 1278-1286)Vrsta gradiva - članek, sestavni delLeto - 2007Jezik - angleškiCOBISS.SI-ID - 25352153
Avtor
Knecht, Wolfgang |
Rozpedowska, E. |
Le Breton, C. |
Willer, M. |
Piškur, Jure, 1960-2014
Teme
Antimetabolites |
Mutation |
Animals |
Antineoplastic Agents |
Therapeutic Use |
Cladribine |
Therapeutic Use |
Cytarabine |
Therapeutic Use |
Directed Molecular Evolution |
Methods |
Drosophila Melanogaster |
Enzymology |
Gene Therapy |
Methods |
Glioblastoma |
Therapy |
Lethal Dose 50 |
Neoplasms |
Therapy |
Osteosarcoma |
Therapy |
Phosphorylation |
Phosphotransferases (Alcohol Group Acceptor) |
Genetics |
Metabolism |
Purines |
Metabolism |
Substrate Specificity |
Transduction, Genetic |
Methods |
Vidarabine |
Analogs & Derivatives |
Therapeutic Use |
Antimetaboliti |
Mutacija |
Substrat, specifičnost |
Antineoplastiki |
Citarabin |
Osteosarkom |
Živali |
Kladribin |
Direktna, molekulska evolucija |
Gensko zdravljenje |
Transdukcija genetična |
Glioblastom |
Fosforilacija |
Vidarabin |
Drosophila melanogaster |
Fosfotransferaze (alkoholno skupino prejemnik) |
Letalna doza 50 |
Novotvorbe |
Purini
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|---|
Knecht, Wolfgang | |
Rozpedowska, E. | |
Le Breton, C. | |
Willer, M. | |
Piškur, Jure, 1960-2014 | 31275 |
Izberite prevzemno mesto:
Prevzem gradiva po pošti
Obvestilo
Gesla v Splošnem geslovniku COBISS
Izbira mesta prevzema
Mesto prevzema | Status gradiva | Rezervacija |
---|
Prosimo, počakajte trenutek.